{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-010595","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.386923+00:00","generated_at":"2026-05-24T03:47:34.795548+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Femasys reports 52% revenue growth in 2024; net loss widens to $18.8M; cash runway into Q3 2025","bullets":["Revenue $1.63M, up 52% YoY; net loss $18.8M ($0.85/sh) vs $14.2M ($0.93/sh) in 2023.","Cash $3.5M at year-end; subsequent $5.4M raise; expects runway into Q3 2025.","R&D $8.2M (+14%) and sales/marketing $4.0M (6x increase) due to FemBloc/FemaSeed launch.","FemBloc received European approval; partnerships with CNY Fertility, HRC Fertility, Boston IVF for FemaSeed.","CEO guides U.S. revenue to increase ~50% in Q1 2025 vs Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-010595","json":"https://secwatch.observer/filing/0001140361-25-010595.json","markdown":"https://secwatch.observer/filing/0001140361-25-010595.md","text":"https://secwatch.observer/filing/0001140361-25-010595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036125010595/0001140361-25-010595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036125010595/ef20046254_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:47:34.795548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}